Your browser is no longer supported. Please, upgrade your browser.
Settings
ADMP [NASD]
Adamis Pharmaceuticals Corporation
Index- P/E- EPS (ttm)-0.62 Insider Own1.06% Shs Outstand148.89M Perf Week16.04%
Market Cap178.30M Forward P/E- EPS next Y-0.20 Insider Trans0.00% Shs Float147.89M Perf Month11.82%
Income-49.40M PEG- EPS next Q-0.06 Inst Own10.80% Short Float6.48% Perf Quarter21.78%
Sales16.50M P/S10.81 EPS this Y-23.30% Inst Trans- Short Ratio3.02 Perf Half Y81.55%
Book/sh0.04 P/B30.75 EPS next Y13.00% ROA-123.70% Target Price- Perf Year33.13%
Cash/sh0.05 P/C25.84 EPS next 5Y- ROE-226.50% 52W Range0.38 - 2.34 Perf YTD153.56%
Dividend- P/FCF- EPS past 5Y9.00% ROI-565.70% 52W High-47.44% Beta1.30
Dividend %- Quick Ratio0.50 Sales past 5Y- Gross Margin9.90% 52W Low227.56% ATR0.08
Employees116 Current Ratio0.60 Sales Q/Q-34.50% Oper. Margin- RSI (14)73.79 Volatility9.37% 6.10%
OptionableYes Debt/Eq1.51 EPS Q/Q-244.90% Profit Margin- Rel Volume47.33 Prev Close1.13
ShortableYes LT Debt/Eq0.26 EarningsJul 19 AMC Payout- Avg Volume3.17M Price1.23
Recom3.00 SMA2018.66% SMA5016.89% SMA20022.00% Volume149,977,766 Change8.85%
May-13-20Upgrade Maxim Group Hold → Buy $1.50
Feb-27-20Downgrade Dawson James Buy → Neutral
Nov-26-19Downgrade Raymond James Outperform → Mkt Perform
Jul-16-19Downgrade B. Riley FBR Neutral → Sell $1.90 → $1.10
Nov-12-18Downgrade B. Riley FBR Buy → Neutral $7.50 → $2.50
May-11-18Reiterated Maxim Group Buy $5 → $10
Mar-23-18Reiterated B. Riley FBR, Inc. Buy $6.25 → $7.50
Dec-05-17Reiterated Maxim Group Buy $13 → $14
Oct-04-17Resumed B. Riley & Co. Buy $9.50
Jul-21-16Reiterated Maxim Group Buy $17 → $10
Dec-01-15Initiated Maxim Group Buy $16
May-29-15Initiated Mizuho Buy $10
Jan-28-14Initiated CRT Capital Buy $15
Oct-18-21 08:55AM  
07:58AM  
07:30AM  
Oct-11-21 05:44PM  
Oct-04-21 07:30AM  
Sep-03-21 12:12PM  
Sep-02-21 10:56AM  
07:30AM  
Aug-24-21 04:05PM  
01:14PM  
07:30AM  
Aug-19-21 07:30AM  
Aug-04-21 04:05PM  
Jul-19-21 04:05PM  
Jul-13-21 08:00AM  
Jul-01-21 08:00AM  
Jun-28-21 07:00AM  
Jun-18-21 08:32AM  
Jun-14-21 09:00AM  
Jun-13-21 02:11PM  
Jun-11-21 07:30AM  
Jun-09-21 07:30AM  
Jun-07-21 09:51AM  
07:30AM  
Jun-01-21 07:30AM  
May-28-21 04:04PM  
May-26-21 03:00PM  
11:30AM  
May-25-21 07:42PM  
02:12PM  
May-17-21 04:05PM  
03:15PM  
07:30AM  
May-12-21 07:30AM  
Apr-15-21 04:39PM  
Apr-13-21 04:03PM  
Apr-12-21 10:28AM  
07:00AM  
Mar-22-21 12:30PM  
Mar-15-21 09:00AM  
Feb-22-21 09:00AM  
Feb-17-21 12:00PM  
09:00AM  
Feb-02-21 04:05PM  
Jan-29-21 09:00AM  
Jan-28-21 04:01PM  
09:00AM  
Jan-26-21 09:00AM  
Jan-22-21 10:47AM  
09:59AM  
Jan-21-21 06:39PM  
04:05PM  
01:27PM  
10:02AM  
08:05AM  
Jan-20-21 01:06PM  
09:00AM  
Jan-08-21 08:30AM  
Dec-01-20 09:00AM  
Nov-18-20 12:24PM  
Nov-16-20 11:55AM  
06:45AM  
Nov-09-20 06:35PM  
05:11PM  
04:30PM  
03:15PM  
Nov-05-20 09:00AM  
Nov-03-20 12:30PM  
Oct-12-20 10:24AM  
Sep-18-20 09:00AM  
Sep-17-20 04:05PM  
Sep-16-20 09:23AM  
Sep-03-20 04:05PM  
Aug-25-20 09:00AM  
Aug-21-20 09:00AM  
Aug-17-20 05:55PM  
04:40PM  
Aug-14-20 09:00AM  
Aug-06-20 12:30PM  
Aug-05-20 04:05PM  
Jul-23-20 09:00AM  
Jul-01-20 09:00AM  
Jun-18-20 09:00AM  
Jun-15-20 09:00AM  
May-27-20 09:00AM  
May-25-20 10:37AM  
May-18-20 04:35PM  
09:00AM  
May-15-20 09:00AM  
May-12-20 08:06AM  
May-11-20 08:35PM  
Apr-29-20 12:00PM  
Apr-23-20 09:00AM  
Apr-21-20 09:00AM  
Apr-15-20 04:05PM  
Apr-01-20 09:00AM  
Mar-30-20 04:40PM  
Feb-21-20 09:15AM  
Feb-19-20 09:00AM  
Jan-03-20 09:31PM  
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candidates for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Marguglio David J.SVP and Chief Business OfficerNov 20Sale0.4035,00014,000287,264Nov 24 04:29 PM
Hopkins Robert OChief Financial OfficerNov 20Sale0.4135,00014,182254,810Nov 24 04:26 PM
Moss Ronald B.Chief Medical OfficerNov 18Sale0.418,5323,465231,752Nov 20 04:38 PM
Hopkins Robert OChief Financial OfficerNov 18Sale0.417,2292,936289,810Nov 20 04:34 PM
CARLO DENNIS J PHDPresident & CEONov 18Sale0.4110,6654,331316,405Nov 20 04:33 PM
Daniels Karen K.VP of OperationsNov 18Sale0.415,3332,166149,242Nov 20 04:32 PM
Marguglio David J.SVP and Chief Business OfficerNov 18Sale0.418,5323,465322,264Nov 20 04:31 PM